Kidney Therapeutics

New drugs for acute kidney injury (AKI) and chronic kidney disease (CKD).

Targeting CKD

Novel, on-target therapies for chronic kidney disease.

Inflammation related AKI

International Phase II trial with LSALT peptide to prevent acute kidney injury (AKI).

Targeting Toxin Related AKI

Cilastatin is a major commercial drug candidate in a Phase II trial to prevent acute kidney injury (AKI).

Investor Relations

Stock information, press releases, financials and management’s discussion and analysis.

New drugs for acute and chronic kidney disease

Arch Biopartners is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio spans both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect millions of patients worldwide.

Arch’s lead drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI, a condition that affects more than 10 million people annually in the U.S. and Europe. AKI represents an ideal initial focus, as success in this area could also pave the way for broader applications in lung and liver inflammation, additional AKI indications, and septic shock.

Arch is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the leading cause of kidney failure worldwide. With CKD affecting more than 800 million people globally and 35–38 million in the U.S. alone, the need for new therapies is profound.

Together, these programs position Arch to address both the acute and chronic sides of kidney disease, advancing first-in-class therapeutics where few effective options exist today.

Find out more about the Company, its focus, and the fundamentals that define Arch’s leadership.

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun The Company has filed both composition and method of use patents relating to the CKD platform. The Arch CKD program will be led by Dr. Justin Chun, who joins the Company as a Principal Scientist CKD is largely an unmet medical need, ...

Full Release

Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General HospitalSt. Michael’s Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites in North America to join the trial TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the first patient has successfully completed dosing at Toronto General Hospital (TGH), part of the University Health Network (UHN), Canada’s largest academic health sciences centre and a global ...

Full Release

Find out about the company’s recent advancements, new patents, corporate filings, information for investors and all progress updates on active clinical trials.

Browse all of the company’s material news releases.
Read the latest releases when they are published here or via email by subscribing to email alerts and news.

Arch Biopartners key stock indicators.

The Stock Performance page displays current and historical data for both of the Arch Biopartners symbols on the TSX Venture Exchange in Canada (ARCH.V) and the OTCQB Venture Exchange (ACHFF) in the USA.

Please be sure to subscribe for email updates when the company issues news releases and to receive announcements of new scientific data and company events and presentations.

The company’s reports and filings include current filings and an archive for investors and the public to use for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR+ website here .

Investor Information

Stock data, insights, filings, latest news.

Subscribe for email updates

Get email alerts when news is published

Latest Scientific Publications

Arch Biopartners science team’s published findings and articles in peer-reviewed journals.

Driving innovation in kidney therapeutics

Kidney disease represents a major unmet need, affecting hundreds of millions worldwide.

Arch is advancing a mechanism-based pipeline spanning both chronic and acute kidney disease, with three programs designed to directly target the underlying drivers of kidney injury and disease.

CKD Platform – Novel Therapeutics for Chronic Kidney Disease

Arch’s IL-32 CKD platform targets a cytokine directly implicated in diabetic kidney disease (DKD), the leading cause of kidney failure worldwide. By focusing on this pathway, the program advances a novel, on-target therapeutic approach that strengthens Arch’s leadership in kidney therapeutics.

LSALT peptide – Blocking Inflammation in Acute Kidney Injury (AKI)

Arch’s lead drug candidate, LSALT peptide (Metablok™), is a first-in-class DPEP1 inhibitor designed to protect the kidneys from ischemia-reperfusion injury. It is now being evaluated in a global Phase II trial for cardiac surgery–associated AKI (CS-AKI).

Cilastatin – Drug Toxin-Related Acute Kidney Injury (AKI)

Cilastatin is a repurposed DPEP1 inhibitor being evaluated for its ability to block toxic drug uptake into the kidneys and prevent toxin-induced AKI. Now in the Phase II PONTiAK trial (700 patients, CIHR/ACT funded), targeting AKI caused by antibiotics, chemotherapeutics, and contrast agents.

Meet the science team.

Arch Biopartners’ scientific leadership brings deep expertise in kidney disease, inflammation biology, and advancing discoveries from the lab to the clinic.

Dr. Daniel Muruve, Chief Science Officer and Co-Founder, leads the Company’s clinical and translational research, with internationally recognized expertise in kidney disease and inflammation.
The scientific team includes leading investigators from the University of Calgary, whose discoveries established the dipeptidase-1 (DPEP1) pathway and LSALT Peptide as first-in-class approaches to prevent inflammation-driven kidney injury.
The addition of Dr. Justin Chun as a Principal Scientist marks Arch Biopartners’ expansion into chronic kidney disease (CKD), advancing a breakthrough platform that targets IL-32 in diabetic kidney disease.

The company’s lead scientists have authored key peer-reviewed papers as part of their ongoing research and development.

Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation, with broad applications to prevent organ and tissue injury.

BMJ Open, March 2024 – Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2
Science Advances, February 2022 – Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury
Cell, August 2019 – Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver

CKD Platform publications are forthcoming and will be made available here. Currently there is a significant abstract published in the Journal of the American Society of Nephrology (JASN), titled IL-32 Is a Lipid Droplet-Associated Mediator of Tubular Injury in Diabetic Kidney Disease.